Performance of ABBV AbbVie | 19.7% in 12m
Compare ABBV with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare AbbVie with its related Sector/Index XBI
Performance Duell ABBV vs XBI
TimeFrame | ABBV | XBI |
---|---|---|
1 Day | 0.97% | -0.02% |
1 Week | 2.59% | -0.33% |
1 Month | 2.30% | -6.54% |
3 Months | 18.8% | 4.44% |
6 Months | 22.0% | 28.65% |
12 Months | 19.7% | 27.48% |
YTD | 15.0% | 5.16% |
Rel. Perf. 1m | 0.76 | |
Rel. Perf. 3m | -0.64 | |
Rel. Perf. 6m | -0.68 | |
Rel. Perf. 12m | -0.50 |
Is AbbVie a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, AbbVie (NYSE:ABBV) is currently (March 2024)
ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 3.84 and therefor a somewhat positive outlook according to fundamental data.
Based on ValueRays Technical Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABBV as of March 2024 is 192.25. This means that ABBV is currently undervalued and has a potential upside of +5.57% (Margin of Safety).
Based on ValueRays Technical Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABBV as of March 2024 is 192.25. This means that ABBV is currently undervalued and has a potential upside of +5.57% (Margin of Safety).
Is ABBV a buy, sell or hold?
- Strong Buy: 8
- Buy: 9
- Hold: 11
- Sell: 0
- Strong Sell: 0
Values above 0%: ABBV is performing better - Values below 0%: ABBV is underperforming
Compare ABBV with Broad Market Indices
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 2.42% | -1.34% | -0.98% | -14.41% |
US NASDAQ 100 | QQQ | 3.01% | 0.16% | -2.54% | -25.81% |
US Dow Jones Industrial 30 | DIA | 2.59% | -0.04% | 2.69% | -5.49% |
German DAX 40 | DBXD | 0.82% | -2.78% | 1.38% | -1.72% |
UK FTSE 100 | ISFU | 1.83% | -2.63% | 11.79% | 6.74% |
Shanghai Shenzhen CSI 300 | CSI 300 | 4.47% | 0.48% | 26.39% | 35.42% |
Hongkong Hang Seng | HSI | 6.13% | 7.02% | 28.06% | 40.28% |
Japan Nikkei 225 | EXX7 | 3.13% | -1.25% | 0.10% | -8.58% |
India NIFTY 50 | INDA | 0.49% | 1.26% | 5.37% | -14.87% |
Brasil Bovespa | EWZ | 2.99% | 5.09% | 11.75% | -9.20% |
ABBV AbbVie vs. Sectors
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 2.58% | -1.79% | -2.52% | -27.79% |
Consumer Discretionary | XLY | 2.83% | 1.69% | 6.67% | -11.05% |
Consumer Staples | XLP | 2.13% | -0.85% | 9.65% | 12.79% |
Energy | XLE | 0.64% | -8.73% | 17.80% | -1.19% |
Financial | XLF | 2.06% | -2.45% | -4.94% | -16.76% |
Health Care | XLV | 1.15% | 0.76% | 7.15% | 1.54% |
Industrial | XLI | 2.34% | -2.44% | -2.69% | -10.67% |
Materials | XLB | 1.56% | -4.98% | 2.65% | -2.20% |
Real Estate | XLRE | 1.44% | -0.27% | 3.49% | 3.65% |
Technology | XLK | 3.34% | 0.39% | -6.02% | -25.93% |
Utilities | XLU | -0.36% | -4.32% | 8.39% | 16.76% |
Aerospace & Defense | XAR | 2.04% | -0.36% | -4.14% | -3.61% |
Biotech | XBI | 2.92% | 8.84% | -6.69% | -7.75% |
Homebuilder | XHB | 2.10% | -7.00% | -23.31% | -51.59% |
Retail | XRT | 1.50% | -1.90% | -9.60% | -11.76% |
Does AbbVie outperform its market, is ABBV a Sector Leader?
No, over the last 12 months AbbVie (ABBV) made 19.73%, while its related Sector, the SPDR S&P Biotech (XBI) made 27.48%.
Over the last 3 months ABBV made 18.80%, while XBI made 4.44%.
No, over the last 12 months AbbVie (ABBV) made 19.73%, while its related Sector, the SPDR S&P Biotech (XBI) made 27.48%.
Over the last 3 months ABBV made 18.80%, while XBI made 4.44%.
Period | ABBV | XBI | S&P 500 |
---|---|---|---|
1 Month | 2.30% | -6.54% | 3.64% |
3 Months | 18.80% | 4.44% | 10.07% |
12 Months | 19.73% | 27.48% | 34.14% |